U
MRNS

UBS’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

UBS’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1K Buy
+40
New +$1.24K ﹤0.01% 10200

Other funds holding MRNS

CPV
Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS's MRNS Position: Q3 2014 in Review

UBS opened a new position in Marinus Pharmaceuticals, Inc (MRNS) in Q3 2014: 40 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #10200 among its holdings.

18 funds tracked by Wall St. Rank hold MRNS as of Q3 2014.

  • UBS held 40 shares of Marinus Pharmaceuticals, Inc worth $1K as of Q3 2014.
  • Marinus Pharmaceuticals, Inc was a new UBS position in Q3 2014.
  • Marinus Pharmaceuticals, Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10200 holding.
  • 18 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.